30/4/2025, 2:42:03 pm

Zydus Life gets final USFDA approval for drug to reduce cholestrol

Zydus Lifesciences has received USFDA final approval for Niacin Extended-Release tablets (500 mg, 750 mg, 1,000 mg) to treat high cholesterol and related conditions. The tablets will be manufactured at its Moraiya facility. The drug generated $5.5 million in annual U.S. sales as of February 2025. Zydus has received 425 approvals and filed 492 ANDAs since 2003-04.